Administration of the Nicotinic Acetylcholine Receptor Agonists ABT-089 and ABT-107 Attenuates the Reinstatement of Nicotine-seeking Behavior in Rats

Overview

Journal Behav Brain Res

Specialties Neurology
Psychology
Social Sciences

Date 2014 Aug 17

PMID 25128791

Citations 8

Authors

Alycia M Lee

Adrian C Arreola

Blake A Kimmey

Heath D Schmidt

Affiliations

Soon will be listed here.

Abstract

Current smoking cessation pharmacotherapies have modest efficacy, and most smokers relapse within the first few days after a quit attempt. Nicotine withdrawal-induced craving and cognitive impairments predict smoking relapse during abstinence and suggest that cognitive-enhancing drugs may prevent relapse. ABT-089 and ABT-107 are subtype-selective nAChR agonists that improve cognitive performance in laboratory animals. However, there are no studies examining the effects of ABT-089 and ABT-107 on nicotine self-administration and the reinstatement of nicotine-seeking behavior, an animal model of relapse in human smokers. The goal of the present study was to determine the effects of the α4β2*/α6β2* nAChR agonist ABT-089 and the α7 nAChR agonist ABT-107 on nicotine taking and seeking in rats. The effects of acute ABT-089 and ABT-107 pretreatment on nicotine self-administration and reinstatement were tested in male Sprague Dawley rats. Parallel studies of ABT-089 and ABT-107 on sucrose self-administration and reinstatement were tested in separate groups of rats to determine if the effects of these drug treatments generalized to other reinforced behaviors. Nicotine and sucrose self-administration behaviors were not altered following acute administration of ABT-089 (0, 0.12, 1.2 and 12.0mg/kg) or ABT-107 (0, 0.03 and 0.3mg/kg). In contrast, both ABT-089 and ABT-107 pretreatment dose-dependently attenuated nicotine reinstatement. These effects were reinforcer-specific as no effects of ABT-089 or ABT-107 pretreatment on sucrose seeking were noted. Taken together, these findings suggest that ABT-089 and ABT-107 do not affect nicotine consumption, but may reduce the likelihood that a smoking lapse will lead to relapse.

Citing Articles

Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.

Herman R, Hayes M, Audrain-McGovern J, Ashare R, Schmidt H Psychopharmacology (Berl). 2023; 240(6):1373-1386.

PMID: 37129617 PMC: 11088902. DOI: 10.1007/s00213-023-06376-w.

Paternal nicotine taking elicits heritable sex-specific phenotypes that are mediated by hippocampal Satb2.

Maurer J, Wimmer M, Turner C, Herman R, Zhang Y, Ragnini K Mol Psychiatry. 2022; 27(9):3864-3874.

PMID: 35595980 PMC: 9675874. DOI: 10.1038/s41380-022-01622-7.

Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse.

Schmidt H, Rupprecht L, Addy N Mol Neuropsychiatry. 2019; 4(4):169-189.

PMID: 30815453 PMC: 6388439. DOI: 10.1159/000494799.

Attenuation of nicotine taking and seeking in rats by the stoichiometry-selective alpha4beta2 nicotinic acetylcholine receptor positive allosteric modulator NS9283.

Maurer J, Sandager-Nielsen K, Schmidt H Psychopharmacology (Berl). 2016; 234(3):475-484.

PMID: 27844094 DOI: 10.1007/s00213-016-4475-7.

Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.

Henningfield J, Smith T, Kleykamp B, Fant R, Donny E Psychopharmacology (Berl). 2016; 233(23-24):3829-3848.

PMID: 27766371 PMC: 5588156. DOI: 10.1007/s00213-016-4441-4.

References

Hopkins T, Rupprecht L, Hayes M, Blendy J, Schmidt H . Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology. 2012; 37(10):2310-21. PMC: 3422495. DOI: 10.1038/npp.2012.83. View

Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh J . Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci. 2008; 28(47):12318-27. PMC: 2819191. DOI: 10.1523/JNEUROSCI.3918-08.2008. View

Tuesta L, Fowler C, Kenny P . Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol. 2011; 82(8):984-95. PMC: 3163076. DOI: 10.1016/j.bcp.2011.06.026. View

Tapper A, McKinney S, Nashmi R, Schwarz J, Deshpande P, Labarca C . Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004; 306(5698):1029-32. DOI: 10.1126/science.1099420. View

Marks M, Wageman C, Grady S, Gopalakrishnan M, Briggs C . Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. Biochem Pharmacol. 2009; 78(7):795-802. PMC: 2772152. DOI: 10.1016/j.bcp.2009.05.022. View

Hays J, Ebbert J, Sood A . Efficacy and safety of varenicline for smoking cessation. Am J Med. 2008; 121(4 Suppl 1):S32-42. DOI: 10.1016/j.amjmed.2008.01.017. View

Rollema H, Hajos M, Seymour P, Kozak R, Majchrzak M, Guanowsky V . Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol. 2009; 78(7):813-24. DOI: 10.1016/j.bcp.2009.05.033. View

Schwartz R, Kellar K . Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science. 1983; 220(4593):214-6. DOI: 10.1126/science.6828889. View

Le Foll B, Chakraborty-Chatterjee M, Lev-Ran S, Barnes C, Pushparaj A, Gamaleddin I . Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. Int J Neuropsychopharmacol. 2011; 15(9):1265-74. PMC: 3707493. DOI: 10.1017/S1461145711001398. View

10.

Wouda J, Riga D, De Vries W, Stegeman M, van Mourik Y, Schetters D . Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl). 2011; 216(2):267-77. PMC: 3121941. DOI: 10.1007/s00213-011-2213-8. View

11.

Yan Y, Pushparaj A, Le Strat Y, Gamaleddin I, Barnes C, Justinova Z . Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats. Neuropsychopharmacology. 2011; 37(3):685-96. PMC: 3260983. DOI: 10.1038/npp.2011.245. View

12.

Grottick A, Trube G, Corrigall W, Huwyler J, Malherbe P, Wyler R . Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther. 2000; 294(3):1112-9. View

13.

Picciotto M, Addy N, Mineur Y, Brunzell D . It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol. 2008; 84(4):329-42. PMC: 2390914. DOI: 10.1016/j.pneurobio.2007.12.005. View

14.

Mogg A, Whiteaker P, McIntosh J, Marks M, Collins A, Wonnacott S . Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther. 2002; 302(1):197-204. DOI: 10.1124/jpet.302.1.197. View

15.

Buccafusco J, Beach J, Terry Jr A . Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther. 2008; 328(2):364-70. PMC: 2682277. DOI: 10.1124/jpet.108.145292. View

16.

Apostol G, Abi-Saab W, Kratochvil C, Adler L, Robieson W, Gault L . Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2011; 219(3):715-25. DOI: 10.1007/s00213-011-2393-2. View

17.

Hughes J . Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007; 9(3):315-27. DOI: 10.1080/14622200701188919. View

18.

Kohlhaas K, Bitner R, Gopalakrishnan M, Rueter L . Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis. Psychopharmacology (Berl). 2011; 220(4):823-33. DOI: 10.1007/s00213-011-2535-6. View

19.

Picciotto M, Corrigall W . Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci. 2002; 22(9):3338-41. PMC: 6758396. DOI: 20026360. View

20.

Ashare R, Schmidt H . Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014; 9(6):579-94. PMC: 4287224. DOI: 10.1517/17460441.2014.908180. View